Search

Displaying results 2641 - 2650 of 8575 in total
  1. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    well as newer agents like [crizanlizumab] and [voxelotor]. … [L49681] In September 2024, the drug was approved by Health Canada for the same indications. [L52850]

  2. Drug

    HMR4011

    go.drugbank.com/drugs/DB06225
    Experimental

    IPL 576,092 has previously been investigated as a treatment for asthma.

  3. Drug

    Dexrazoxane

    go.drugbank.com/drugs/DB00380
    ApprovedInvestigationalWithdrawn

    [PubChem] The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

    Synonyms: (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane, 2,6-Piperazinedione, 4, 4'-(1-methyl-1,2-ethanediyl)bis-, (S)- (9CI)
  4. Drug

    Ebola Zaire vaccine (live, attenuated)

    go.drugbank.com/drugs/DB15595
    ApprovedInvestigational

    These may be accompanied by hypotension and respiratory, kidney and liver failure, as well as internal and external bleeding. … [A189018] This vaccine was later sold to NewLink Genetics, a biotech company that held the license to the vaccine from 2010 to 2014, although the vaccine was not marketed.

  5. Drug

    Liotrix

    go.drugbank.com/drugs/DB01583
    Approved

    Liotrix was developed when it was believed that serum levels of both T4 and T3 were maintained by direct thyroidal secretion.

  6. Drug

    NOV-002

    go.drugbank.com/drugs/DB05393
    Investigational

    NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. … NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy.

  7. Drug

    Tetraferric tricitrate decahydrate

    go.drugbank.com/drugs/DB14520
    ApprovedInvestigational

    [A25965] Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014.[L9926]

  8. Drug

    Liposomal prostaglandin E1

    go.drugbank.com/drugs/DB05391
    Investigational

    Liposome-encapsulated form of prostaglandin E1 (Liprostin) is known to be a potent vasodilator and platelet inhibitor as well as an anti-inflammatory and anti-thrombotic agent.

  9. Drug

    Crisaborole

    go.drugbank.com/drugs/DB05219
    ApprovedInvestigational

    It is currently under development as topical treatment of psoriasis. … Crisaborole is a novel oxaborole approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis.

  10. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    Mirabegron has a comparatively favorable adverse effect profile as compared to other available treatment options, and its complementary mechanism to the antimuscarinics that came before it allows for its … [L32853] An extended-release granule formulation was subsequently granted approval in March 2021 for the treatment of pediatric patients with neurogenic detrusor overactivity.